Rasagiline and safinamide as a dopamine-sparing therapy for parkinson's disease

Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease

Expert Opin Drug Metab Toxicol.

Müller T

doi: 10.1080/

Anxiety and Depression

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease

J Parkinsons Dis.

Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C

doi: 10.3233/JPD-171143.

Parkinson’s Disease

Initiation of pharmacological therapy in Parkinson's disease: when, why, and how

Lancet Neurol.

de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE

doi: 10.1016/S1474-4422(20)30036-3.

Safinamide: A Review in Parkinson's Disease

CNS Drugs.

Blair HA, Dhillon S

doi: 10.1007/s40263-017-0408-1.

Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study

J Neurol.

Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL, Pezzoli G

doi: 10.1007/s00415-017-8523-y.

Safinamide for the treatment of Parkinson's disease

Expert Opin Pharmacother.

Scott RM, Schapira A

doi: 10.1080/

Anxiety and Depression

Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial

Lancet Neurol.

Lhommée E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, Hälbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-Döring F, Kupsch A, Krüger R, Elben S, Chabardès S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis JM, Maltête D, Sauvaget A, Rau J, Schnitzler A, Schüpbach M, Schade-Brittinger C, Deuschl G, Houeto JL, Krack P; EARLYSTIM study group

doi: 10.1016/

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort

JAMA Neurol.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators

doi: 10.1001/jamaneurol.

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.